Innoviva, Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Pavel Raifeld C.F.A.
- Full Time Employees
- 112
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1350 Old Bayshore Highway Burlingame CA United States of America 94010
- IPO Date
- Oct 5, 2004
- CIK
- 0001080014
- Website
- inva.com
- Similar Companies
- Business
- Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Company News
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
3 Under-$20 Stocks That Could Make You a Fortune
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Innoviva to Participate in the BofA Securities Health Care Conference
Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
Innoviva: A Lot Of Moving Parts
Innoviva to Participate in the Cantor Global Healthcare Conference